| Document |
Document Title |
|
WO/2022/226166A1 |
Provided herein are compounds of formula I that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the c...
|
|
WO/2022/225379A1 |
The present invention provides a device for treating an overactive bladder, comprising: a guide part which can be worn on a foot, and which includes a band part in the form of a vertically elongated band, and a marker positioned at one e...
|
|
WO/2022/225044A1 |
Provided is a novel drug that is useful for improving prognosis of a patient of hyperkalemia complicated by CKD. The present invention pertains to an agent for improving prognosis of a patient of hyperkalemia complicated by CKD, said a...
|
|
WO/2022/223650A1 |
The present invention relates to a composition for use in inhibition of crystallization and/or biofilm formation on an indwelling urinary catheter. The composition of the present invention comprises magnesium ions, potassium ions and cit...
|
|
WO/2022/222971A1 |
Disclosed is an oral enteric-coated corticosteroids pharmaceutical composition, including: a) a sustained release component, wherein the sustained release component contains a drug-containing core, an isolation layer and a sustained-rele...
|
|
WO/2022/221886A1 |
Provided herein are pharmaceutical compositions for the treatment of benign prostatic hypertrophy comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further p...
|
|
WO/2022/220265A1 |
Provided is a novel use of S-1-propenylcysteine, a salt thereof or a composition containing the same. A Sirtuin or Klotho activator or expression enhancer that comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
|
|
WO/2022/216871A1 |
Apelin receptor modulators can improve physical performance, slow progression of age-related frailty, and can reduce age-related muscle weakness in human patients. This disclosure provides methods for treating muscle conditions using a p...
|
|
WO/2022/216287A1 |
The invention provides a formulation and method for the treatment of urinary system disorders, wherein the formulation comprises a controlled release drug delivery system for intravesicular administration to a patient. Controlled release...
|
|
WO/2022/189856A9 |
This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising...
|
|
WO/2022/171732A9 |
The invention relates to a composition comprising Lumasiran and/or Nedosiran for use in the treatment or prevention of an oxalate-related disorder in a patient receiving dialysis treatment who does not suffer from Primary Hyperoxaluria 1...
|
|
WO/2022/215704A1 |
The present invention pertains to a conjugate body represented by Lg-Lk-NCA wherein Lk is a linker moiety, NCA is a nucleic acid moiety and Lg is a group represented by one of the formulae.
|
|
WO/2022/215950A1 |
The present invention relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one in treating kidney disease. According to the present invention, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phen...
|
|
WO/2022/217105A1 |
An ionic, electrically activated, aqueous or dry mixture includes dissolved minerals, undissolved minerals, and inert, structured, mineral microparticles. The aqueous or dry mixture may be formulated to make the active ingredients system...
|
|
WO/2022/216129A1 |
The present invention relates to glucagon derivatives and use thereof.
|
|
WO/2022/214108A1 |
An AK183 protease-based recombinant fusion protein, and an application thereof in preparing a drug for IgA nephropathy and other related diseases mediated by IgA complex deposition. The recombinant fusion protein structure includes a hum...
|
|
WO/2022/211574A1 |
The present invention relates to a composition for preventing or treating chronic kidney diseases (CKDs), comprising a compound that induces the expression of anti-aging gene klotho. The composition represented by chemical formula 1, acc...
|
|
WO/2022/210829A1 |
Provided is a tablet: containing 55-95 mass% abiraterone acetate, as an active ingredient, to the total mass of the tablet, a solubilizing agent, and an aluminate metasilicate; being a small tablet having the content of abiraterone aceta...
|
|
WO/2022/206857A1 |
Provided herein are an ETAR antibody and a pharmaceutical composition thereof, also provided herein is a method for treating, preventing or ameliorating one or more symptoms of diabetic nephropathy and one or more symptoms of chronic nep...
|
|
WO/2022/208430A1 |
The invention pertains to host cells for producing a bioconjugate of an E. coli O18 antigen polysaccharide conjugated to a carrier protein. The host cells are characterized in that they comprise modified Wzy O-antigen polymerases with sp...
|
|
WO/2022/205021A1 |
The present invention relates to the field of biotechnologies, and in particular, to an anti-ANGPTL3 antibody or an antigen-binding fragment thereof. According to the anti-ANGPTL3 antibody or the antigen-binding fragment thereof provided...
|
|
WO/2022/208375A1 |
Compound with formula (1) for use in a method for treating a disease or disorder capable of being treated by an agonist of AdipoR. e.g. diabetic neuropathy.
|
|
WO/2022/206705A1 |
The present invention provides a heterocyclic compound as a TYK2 pseudokinase (JH2) domain inhibitor, a synthetic method, and use. In particular, the present invention provides a heterocyclic compound as represented by formula I, or a ph...
|
|
WO/2022/204907A1 |
Provided is a method for preparing a cocrystal of L-pyroglutamic acid and a glucopyranosyl derivative, which can be used as a sodium-dependent glucose transporter (SGLT) inhibitor. The method is stable and controllable, so the target coc...
|
|
WO/2022/206666A1 |
Provided are a crystalline form of a pyrrole amide compound, a preparation method therefor and a use thereof, and also provided is a pharmaceutical composition comprising the crystalline form. In particular, the crystalline form or the p...
|
|
WO/2022/203432A1 |
A pharmaceutical composition according to the present invention comprises, as an active ingredient, a specific amount of dimethyl fumarate or monomethyl fumarate, or pharmaceutically acceptable salts thereof, the pharmaceutical compositi...
|
|
WO/2022/200578A1 |
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The c...
|
|
WO/2022/202761A1 |
[Problem] To provide a peptide complex capable of binding to c-Met protein. [Solution] Provided is a peptide complex containing a peptide A, in which the peptide A is a peptide comprising the amino acid sequence represented by X1-X2-X3-V...
|
|
WO/2022/204100A1 |
The present invention provides a compound of Formula I: wherein R is hydrogen, -P(=O)(OH)2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treat...
|
|
WO/2022/200580A1 |
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof.The co...
|
|
WO/2022/200786A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, includ...
|
|
WO/2022/200787A1 |
There is provided pharmaceutical compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, incl...
|
|
WO/2022/200785A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, i...
|
|
WO/2022/204099A1 |
The present invention provides a compound of Formula I: (I) wherein R1 is H, halogen, C1-C3 alkyl, or C1-C3 alkoxy; R2 is H or halogen; and X is O, OCH2, or CH2, or a pharmaceutically acceptable salt thereof, wherein the compound of Form...
|
|
WO/2022/200463A1 |
This disclosure relates to a combination therapy for treating subjects having a fibrotic disorder. More particularly, the disclosure relates to combination therapies comprising an AXL inhibitor (AXLi) and a renin-angiotensin system inhib...
|
|
WO/2022/201161A1 |
Provided herein are methods for treating nephrolithiasis and protecting the urothelium and inner lining of the kidney from thermal damage during lithotripsy by use of a thermosensitive bio-adhesive hydrogel. The described method dramatic...
|
|
WO/2022/196816A1 |
Provided are a colicin-fighting monoclonal antibody molecule or a derivative thereof, and a pharmaceutical composition containing the same, for ameliorating acute lung injury and acute worsening of pulmonary fibrosis. The pharmaceutica...
|
|
WO/2022/198192A1 |
The present disclosure provides methods for treating lupus nephritis in an individual that is greater than or equal to 12 years of age and less than 18 years of age. In some embodiments, the methods comprise administering to the individu...
|
|
WO/2022/196683A1 |
Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. A serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxi...
|
|
WO/2022/197641A1 |
The present invention relates to 1H-pyrazolo[3,4-d]pyrimidin-6-yl- amine derivatives of formula (I) as hematopoietic progenitor kinase 1 (HPK1) modulators and/or inhibitors for the treatment of cancer and other diseases, such as e.g. vir...
|
|
WO/2022/188762A1 |
A pharmaceutical composition for treating or alleviating a hangover from alcohol, which comprises radix codonopsis pilosulae, poria, and pericarpium citri reticulatae, or further comprises rhizoma zingiberis and rhizoma atractylodis macr...
|
|
WO/2022/189010A1 |
Described herein are compositions and methods of alleviating, preventing, reducing, suppressing, and/or treating a bacterial infection in a human or non-human animal. The compositions and methods are useful in supporting, for example, ge...
|
|
WO/2022/191194A1 |
One of the problems addressed by the present invention is the provision of an agent for inhibiting renal damage induced by rhabdomyolysis. The present invention uses cilastatin or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/192545A1 |
Provided herein are alpha V beta 6 and alpha V beta 1 integrin inhibitors, methods of making such alpha V beta 6 and alpha V beta 1 integrin inhibitors, pharmaceutical compositions of alpha V beta 6 and alpha V beta 1 integrin inhibitors...
|
|
WO/2022/191193A1 |
One of the problems of the present invention is to provide an agent for preventing a kidney injury induced by a hemolytic reaction. In the present invention, cilastatin or a pharmaceutically acceptable salt thereof is used.
|
|
WO/2022/184755A1 |
The present invention relates to Galectin-3 inhibitors of Formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds, and their medical uses.
|
|
WO/2022/186813A1 |
Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat d...
|
|
WO/2022/184000A1 |
A novel imidazole compound serving as a TGF-β inhibitor, and in particular a TGFβR-1 inhibitor, a pharmaceutical composition comprising the compound, and a use of the compound and the composition in the prevention and/or treatment of T...
|
|
WO/2022/187419A1 |
The present disclosure provides compounds of Formula (I): and the salts or solvates thereof, wherein A1, B1, L, and X2 are as defined in the specification. The present disclosure also relates to uses of the compounds, e.g., asandrogen re...
|
